Back to results
US 2014/0275102 A1Published application
Solid State Forms of 6-[4-[3-((R)-2-Methylpyrrolidine-1-yl)-propoxy]phenyl] 2H-pyridazine-3-one Hydrochloride
AssigneeCephalon, Inc.
InventorsStephen J. Bierlmaier, Laurent Courvoisier, Ralph C. Haltiwanger, Martin J. Jacobs
Life of this patent
Estimating the term…
Abstract
Solid state forms of the compound 6-[4-[3-((R)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2H-pyridazine-3-one hydrochloride (Compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine H3 receptor antagonist/inverse agonist. Thus the provided solid state forms are useful, for example, for the manufacture of a medicament for the treatment of disorders mediated by the H3 receptor.
Claims20
Crystalline form A1 of Compound 1:
- characterized by an X-ray powder diffraction pattern having any selection of from five to ten X-ray powder diffraction peaks selected from 3.75, 10.98, 14.62, 15.25, 15.55, 15.88, 16.48, 16.64, 17.19, 18.26, 20.63, 21.08, 21.67, 23.02, 23.29, 23.56, 24.43, 25.78, 26.07, 26.28, 26.33, 27.42, 27.95, 28.40, 29.35, and 29.77 degrees two theta±0.2 degrees two theta.
Crystalline form H4A1 of Compound 1:
- characterized by an X-ray powder diffraction pattern having any selection of from five to eight X-ray powder diffraction peaks selected from 5.72, 11.40, 12.95, 16.45, 17.11, 17.34, 21.45, and 22.26 degrees two theta±0.2 degrees two theta.
Crystalline form B1 of Compound 1:
- characterized by an X-ray powder diffraction pattern having peaks at 6.87, 13.79, 15.76, 19.25 and 25.79 degrees two theta±0.2 degrees two theta.
Dependencies are inferred from the claim text.